Research programme: transient receptor potential channel inhibitors - Johnson & Johnson

Drug Profile

Research programme: transient receptor potential channel inhibitors - Johnson & Johnson

Alternative Names: 2,7-diamino-thiazolo[5,4-d]pyrimidine derivatives - Johnson & Johnson; JNJ 17203212; TRPM8 antagonists - Johnson & Johnson; TRPV1 antagonists - Johnson & Johnson

Latest Information Update: 03 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson
  • Class Benzimidazoles; Heterocyclic bicyclo compounds; Pyrimidines; Spiro compounds; Thiazoles
  • Mechanism of Action TRPM8 protein inhibitors; TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cough; Pain

Most Recent Events

  • 26 Aug 2010 Pharmacodynamics data from preclinical studies in pain presented at the 240th American Chemical Society National Meeting (240th-ACS-2010) .
  • 21 Aug 2008 Pharmacodynamics data from a preclinical trial in Pain presented at the 236th American Chemical Society National Meeting (236th-ACS-2008)
  • 07 Nov 2007 Pharmacodynamics data from a preclinical model of bladder pain presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top